|
【结 构 式】 
|
【分子编号】28391 【品名】(3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 【CA登记号】 |
【 分 子 式 】C40H71NO13 【 分 子 量 】774.00268 【元素组成】C 62.07% H 9.25% N 1.81% O 26.87% |
合成路线1
该中间体在本合成路线中的序号：(III)The alkylation of 2',4''-di-O-(trimethylsilyl)erythromycin A 9-O-(1-isopropoxycyclohexyl)oxime (I) with allyl bromide (II) by means of potassium tert-butoxide in DMSO/THF, followed first by acidification with acetic acid and then by treatment with NaHSO3/HCO2H, gives 6-O-allylerythromycin A (III), which is acylated with acetic anhydride in acetonitrile, yielding the diacetate (IV). Reaction of (IV) with either carbonyldiimidazole (CDI) and LiH or CDI and sodium hexamethyldisilazane (NaHMDS) in THF affords the 12-O-(imidazolylcarbonyl)erythromycin derivative (V), which is cyclized with NH4OH in acetonitrile / THF, giving the cyclic carbamate (VI). Elimination of the cladinose group of (VI) by treatment with HCl in ethanol/water followed by reaction with N-chlorosuccinimide (NCS) and dimethyl sulfide in dichloromethane provides the ketolide (VII), which is condensed with 3-bromoquinoline (VIII) under Heck coupling conditions, palladium acetate, tris(o-tolyl)phosphine and Et3N in acetonitrile, and finally deprotected with MeOH 60-80%.
| 【1】 Ma, Z.; et al.; Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J Med Chem 2001, 44, 24, 4137. |
| 【2】 Or, Y.; Clark, R.F.; Ma, Z.; Design, synthesis, and characterization of ABT-773: A novel ketolide highly active against multidrug-resistant pathogens. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26 1999, San Francisco) 1999, Abst F2133. |
| 【3】 Ewing, P.; Or, Y.S.; Nilius, A.M.; Wang, S.; Clark, R.F.; Alder, J.; Chu, D.T.W.; Mitten, M.; Flamm, R.K.; Ma, Z.; Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J Med Chem 2000, 43, 6, 1045-49. |
| 【4】 Rabasseda, X.; Sorbera, L.A.; Castañer, J.; ABT-773. Drugs Fut 2000, 25, 5, 445. |
| 【5】 Adachi, T.; Sekiguchi, K.; Sota, K.; Asaka, T.; Matsunaga, T.; Morimoto, S.; Watanabe, Y.; Kashimura, M. (Taisho Pharmaceutical Co., Ltd.); Erythromycin A derivs.. EP 0272110; US 4990602 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 35291 | C52H100N2O14Si2 | 详情 | 详情 | ||
| (II) | 11463 | 3-Bromo-1-propene; 3-Bromopropene；allyl bromide | 106-95-6 | C3H5Br | 详情 | 详情 |
| (III) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (IV) | 35292 | C44H75NO15 | 详情 | 详情 | ||
| (V) | 35293 | C48H75N3O15 | 详情 | 详情 | ||
| (VI) | 35294 | C45H74N2O15 | 详情 | 详情 | ||
| (VII) | 35295 | C35H56N2O11 | 详情 | 详情 | ||
| (VIII) | 28432 | 3-bromoquinoline | 5332-24-1 | C9H6BrN | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(III)Acidic hydrolysis of the cladinose sugar of 6-O-allylerythromycin A (III) with HCl in ethanol/water yields the 3-hydroxy intermediate (IX), which is first protected at the 2'-OH group with acetic anhydride or benzoyl anhydride to (Xa) or (Xb) and then oxidized with NCS and dimethyl sulfide to the 3-oxoerythromycin derivatives (XIa) or (XIb). The reaction of (XIa) with CDI and LiH or (XIb) first with CDI and NaHMDS, then with DBU and finally with CDI and NaH, provides the 12-O-(1-imidazolylcarbonyl)erythromycin derivatives (XIIa) and (XIIb), which are cyclized with aqueous ammonia to the cyclic carbamates (VII) and (XIIIb). Finally, these compounds are condensed with 3-bromoquinoline (VIII) by means of palladium acetate, tris(o-tolyl)phosphine and Et3N in acetonitrile and deprotected with methanol 60-80%.
| 【1】 Ma, Z.; et al.; Novel erythromycin derivatives with aryl groups tethered to the C-6 position are potent protein synthesis inhibitors and active against multidrug-resistant respiratory pathogens. J Med Chem 2001, 44, 24, 4137. |
| 【2】 Or, Y.; Clark, R.F.; Ma, Z.; Design, synthesis, and characterization of ABT-773: A novel ketolide highly active against multidrug-resistant pathogens. 39th Intersci Conf Antimicrob Agents Chemother (Sept 26 1999, San Francisco) 1999, Abst F2133. |
| 【3】 Ewing, P.; Or, Y.S.; Nilius, A.M.; Wang, S.; Clark, R.F.; Alder, J.; Chu, D.T.W.; Mitten, M.; Flamm, R.K.; Ma, Z.; Design, synthesis, and antimicrobial activity of 6-O-substituted ketolides active against resistant respiratory tract pathogens. J Med Chem 2000, 43, 6, 1045-49. |
| 【4】 Rabasseda, X.; Sorbera, L.A.; Castañer, J.; ABT-773. Drugs Fut 2000, 25, 5, 445. |
| 【5】 Or, Y.S.; Ma, Z.; Clark, R.F.; Chu, D.T.; Plattner, J.J. (Abbott Laboratories Inc.); 6-O-Substd. ketolides having antibacterial activity. EP 0929563; US 5866549; WO 9809978 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (Xb) | 28430 | (2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C39H61NO11 | 详情 | 详情 | |
| (XIb) | 28431 | (2S,3R,4S,6R)-2-[[(3R,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-12,13-dihydroxy-3,5,7,9,11,13-hexamethyl-2,4,10-trioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C39H59NO11 | 详情 | 详情 | |
| (Xa) | 35296 | (2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl acetate | C34H59NO11 | 详情 | 详情 | |
| (XIa) | 35297 | (2S,3R,4S,6R)-2-[[(3R,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-12,13-dihydroxy-3,5,7,9,11,13-hexamethyl-2,4,10-trioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl acetate | C34H57NO11 | 详情 | 详情 | |
| (XIIa) | 35298 | (2R,3S,7R,9S,10R,11R,13R)-10-[[(2S,3R,4S,6R)-3-(acetoxy)-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl]oxy]-9-(allyloxy)-2-ethyl-3,5,7,9,11,13-hexamethyl-6,12,14-trioxooxa-4-cyclotetradecen-3-yl 1H-imidazole-1-carboxylate | C38H57N3O11 | 详情 | 详情 | |
| (XIIb) | 35299 | (2R,3S,7R,9S,10R,11R,13R)-9-(allyloxy)-10-[[(2S,3R,4S,6R)-3-(benzoyloxy)-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-2-yl]oxy]-2-ethyl-3,5,7,9,11,13-hexamethyl-6,12,14-trioxooxa-4-cyclotetradecen-3-yl 1H-imidazole-1-carboxylate | C43H59N3O11 | 详情 | 详情 | |
| (XIIIb) | 35300 | (2S,3R,4S,6R)-2-[[(3aS,4R,7R,9R,10R,11S,13R,15R,15aR)-11-(allyloxy)-4-ethyl-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxotetradecahydro-2H-oxacyclotetradecino[4,3-d][1,3]oxazol-10-yl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C40H58N2O11 | 详情 | 详情 | |
| (III) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (VII) | 35295 | C35H56N2O11 | 详情 | 详情 | ||
| (VIII) | 28432 | 3-bromoquinoline | 5332-24-1 | C9H6BrN | 详情 | 详情 |
| (IX) | 28249 | 2-[3-benzyl-8-(benzyloxy)-2-ethyl-1-indolizinyl]acetamide | C26H26N2O2 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(IV)Alkylation of silylated erythromycin oxime (I) with allyl bromide in the presence of t-BuOK provided allyl ether (II). After acid hydrolysis of the cyclo hexylidene ketal of (II), the oxime group was removed by treatment with NaHSO3 and formic acid to afford ketone (IV). Subsequent cleavage of the 3-O-cladinose unit of (IV) by hydrolysis with HCl furnished ketolide (V). The 2'-hydroxyl group of (V) was then protected by benzoylation with benzoic anhydride yielding (VI).
| 【1】 Flamm, R.K.; Raney, P.M.; Nilius, A.M.; Bui, M.; Or, Y.S.; Wang, S.; Plattner, J.J.; Ma, Z.; Clark, R.; Chu, D.T.W.; Synthesis and antibacterial activity of 6-O-substituted ketolides. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-126. |
| 【2】 Or, Y.S.; Ma, Z.; Clark, R.F.; Chu, D.T.; Plattner, J.J. (Abbott Laboratories Inc.); 6-O-Substd. ketolides having antibacterial activity. EP 0929563; US 5866549; WO 9809978 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28429 | (3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C32H57NO10 | 详情 | 详情 | |
| (VI) | 28430 | (2S,3R,4S,6R)-2-[[(3R,4S,5S,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-14-ethyl-4,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl]oxy]-4-(dimethylamino)-6-methyltetrahydro-2H-pyran-3-yl benzoate | C39H61NO11 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(IV)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Wang, S.; Ma, Z.; Clark, R.F.; et al.; Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. Bioorg Med Chem Lett 2000, 10, 8, 815. |
| 【3】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号：(IV)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function of (III) was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |
合成路线6
该中间体在本合成路线中的序号：(IV)Alkylation of protected erythromycin (I) at the 6-hydroxyl group with allyl bromide provided ether (II). Hydrolysis of the cyclohexylidene ketal group of (II) with concomitant desilylation with AcOH gave (III). The oxime function of (III) was then hydrolyzed using either sodium bisulfite and formic acid or sodium nitrite and HCl to afford ketone (IV). Dihydroxylation of the allyl group of (IV) by means of N-methylmorpholine-N-oxide and a catalytic amount of OsO4, followed by oxidative cleavage of the resulting glycol (V) with NaIO4 produced aldehyde (VI). Alternatively, aldehyde (VI) was obtained by ozonolysis of the allyl ether (IV).
| 【1】 Bui, M.H.; Plattner, J.J.; Ramney, p.M.; Nilius, A.M.; Chu, D.T.W.; Or, Y.S.; Wang, S.; Clark, R.F.; Henry, R.F.; Ma, Z.; Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. 38th Intersci Conf Antimicrob Agents Chemother (Sept 24 1998, San Diego) 1998, Abst F-125. |
| 【2】 Wang, S.; Ma, Z.; Clark, R.F.; et al.; Synthesis and antibacterial activity of novel 6-O-substituted erythromycin A derivatives. Bioorg Med Chem Lett 2000, 10, 8, 815. |
| 【3】 Or, Y.S.; Chu, D.T.; Clark, R.F.; Ma, Z. (Abbott Laboratories Inc.); 6-O-Substd. erythromycins and method for making them. EP 0918783; EP 1007530; JP 2000509712; US 6075011; WO 9742204; WO 9742206 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 28388 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-7,12,13-trihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C54H104N2O12Si2 | 详情 | 详情 | |
| (II) | 28389 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-([(2S,3R,4S,6R)-4-(dimethylamino)-6-methyl-3-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-14-ethyl-12,13-dihydroxy-4-([(2R,4R,5S,6S)-4-methoxy-4,6-dimethyl-5-[(trimethylsilyl)methyl]tetrahydro-2H-pyran-2-yl]oxy)-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-[O-(1-isopropoxycyclohexyl)oxime] | C57H108N2O12Si2 | 详情 | 详情 | |
| (III) | 28390 | (3R,4S,5R,6R,7S,9R,11S,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione 10-oxime | C40H72N2O13 | 详情 | 详情 | |
| (IV) | 28391 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(allyloxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H71NO13 | 详情 | 详情 | |
| (V) | 28392 | (3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-7-(2,3-dihydroxypropoxy)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-oxacyclotetradecanedione | C40H73NO15 | 详情 | 详情 | |
| (VI) | 28393 | 2-[((3R,4S,5R,6R,7S,9R,11R,12R,13S,14R)-6-[[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-14-ethyl-12,13-dihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy]-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecanyl)oxy]acetaldehyde | C39H69NO14 | 详情 | 详情 |